Zydus Cadila gets nod for H1N1 vaccine

Zydus Cadilla, an Ahmedabad, India-based drug company, announced  that it has become the first Indian firm to market the country’s first H1N1 flu vaccine, officials told

The egg-based vaccine will be marketed under the the brand name VaxiFlu-S. The firm said that it intends to develop a variety of vaccines to combat viral and bacterial infections.

“With the vaccine in the market soon, we would be better prepared with an affordable therapy and prevent further loss of lives to this infectious disease,” Pankaj R. Patel, Zydus Cadilla's chairman and marketing director, told “The launch of VaxiFlu-S gives thrust to our objective of emerging as a strong player in the area of preventives.”

Twenty-three percent of the 139,466 people who have been tested for flu-like symptoms in India as of may 10 have tested opsitive for H1N1 at a five percent fatality rate.

In a separate development, the company also announced it will be entering a licensing deal with Abbott Laboratories of the U.S. Under the licensing deal, Abbott will license 24 Zydus Cadilla products in 15 different markets.

“The Zydus agreement complements Abbott’s established products strategy, augmenting this business with a broad portfolio of branded generics,” Olivier Bohuon, executive vice-president of Abbott’s pharmaceutical products group, said.